The present invention relates to an antibody capable of binding with highaffinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4. The invention specifically refers to said antibody possessing the ability to uniquely induce programmed cell death through canonical caspase-dependent apoptosis or authophagy, 5 in cancer cells specifically expressing such protein, and without the participation of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention as pharmaceutical excipients.
Pro-apoptotic anti-NG2/CSPG4 antibodies and their uses in disease therapy / Perris, R; Dallatomasina, A; Tamburini, E; NicolosiPA, ; Mucignat, Mt. - ELETTRONICO. - (2016).
Pro-apoptotic anti-NG2/CSPG4 antibodies and their uses in disease therapy
Perris R;Dallatomasina A;Tamburini E;
2016
Abstract
The present invention relates to an antibody capable of binding with highaffinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4. The invention specifically refers to said antibody possessing the ability to uniquely induce programmed cell death through canonical caspase-dependent apoptosis or authophagy, 5 in cancer cells specifically expressing such protein, and without the participation of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention as pharmaceutical excipients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
